Effect of Inulin on Gut Microbiota and Gut Barrier in Chronic Kidney Disease

Last updated: June 24, 2024
Sponsor: Charite University, Berlin, Germany
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Inulin

Placebo

Clinical Study ID

NCT05071131
RESTORE
  • Ages 18-75
  • All Genders

Study Summary

An adequate fiber intake is crucial for a well-balanced diet and reduces the risk of chronic diseases. However, nutritional recommendations for chronic kidney disease patients lead to an insufficient fiber intake with possible maladaptive effects on the gut microbiome. Therefore, we want to study the effects of a 35-day inulin supplementation on the gut microbiome, gut barrier function, bacterial metabolites and immune cell states in chronic kidney disease patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Men and women in a ratio of 1:1

  • Age 18-75 years

  • Body mass index 25.0 - 39.9 kg/m^2

  • End-stage kidney disease, which has been treated regularly with hemodialysis for atleast 3 months

Exclusion

Exclusion Criteria:

  • Malignant diseases

  • Recent or current hospitalization

  • Postoperative phase

  • Acute infections

  • Malnutrition

  • Antibiotic treatment within the last 4 weeks

  • Regular intake of probiotics and/or prebiotics

  • Change of body weight of more than 2 kg in the month prior to study entry

  • Known drug or alcohol abuse

Changes applied in July 2022 according to amendment no. 1:

  • Two inclusion criteria were changed to improve recruitment

  • Age range was changed from 18-70 to 18-75 years

  • BMI range was changed from 18.5 - 34.9 to 25.0 - 39.9 kg/m^2

  • The intervention scheme was adapted to increase patient adherence

  • A 7-day adaption phase with half of the dose (15 grams per day) at the start ofthe intervention was introduced, changing treatment duration from 28 to 35 days

Changes applied in January 2024 according to amendment no. 2:

  • One inclusion criteria was changed to improve recruitment

  • BMI range was changed from 25 - 39,9 to 18,5 - 39,9 kg/m²

  • Last visit was brought foward by 4 weeks.

Study Design

Total Participants: 40
Treatment Group(s): 2
Primary Treatment: Inulin
Phase:
Study Start date:
February 01, 2022
Estimated Completion Date:
February 01, 2027

Connect with a study center

  • Experimental and Clinical Research Center

    Berlin, 13125
    Germany

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.